Loading news...
Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) has, in today's trading update for the fourth quarter, reported a total portfolio contribution of $57 million for the year ended 31 December. The group noted that the Q4 portfolio contribution amounted to $14.3 million.
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD.
ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025.
electroCore (NASDAQ: ECOR - Get Free Report) and Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Earnings and Valuation This table compares electroCore and
Shares of electroCore, Inc. (NASDAQ: ECOR - Get Free Report) traded up 1.4% on Friday. The stock traded as high as $4.96 and last traded at $4.95. 19,108 shares were traded during mid-day trading, a decline of 46% from the average session volume of 35,493 shares. The stock had previously closed at $4.88. Wall Street
electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript
ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has reported new assay results from operator NexGen Energy showing the highest-grade mineralisation so far at the Patterson Corridor East uranium project in Canada. The royalties-focused investor said these results represent the strongest reported grades to date from the project - and directed investors to the full NexGen announcement for further technical information.
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.
electroCore, Inc. ( ECOR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Daniel Goldberger - CEO & Director Thomas Errico - Founder & Independent Chairman Joshua Lev - Chief Financial Officer Conference Call Participants Rob Fink - FNK IR LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Walter Schenker - MAZ Capital Advisors, LLC Presentation Rob Fink FNK IR LLC Greetings, everyone, and welcome to the electroCore Third Quarter 2025 Earnings Conference Call.
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.31 per share a year ago.
Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) CEO Marc Bishop Lafleche talked with Proactive about the company's record Q3 performance and updated full-year guidance. The update revealed a 112% increase in portfolio contribution compared to Q2 2025, driven largely by base metals royalties.
electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has edged closer to a long-awaited payday from its stake in the Santo Domingo copper project, after...
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has edged closer to a long-awaited payday from its stake in the Santo Domingo copper project, after Capstone Copper confirmed a $360m investment from Orion Resource Partners for a 25% holding. RBC calls the move a “key milestone” towards a construction decision expected in the second half of 2026, with project financing and detailed engineering now the next steps.
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company's Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore's Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were granted as an inducement material to Ms. Hayes' commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Ms. Hayes' continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock.
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI).
ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium.